DNMDP
Based on 4 publication(s) in Google Scholar
DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity.
For research use only. We do not sell to patients.
- Purity: 99.46%
- CAS No.: 328104-79-6
- Formula: C15H20N4O3
- Molecular Weight:304.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) DNMDP
More
Biological Activity
|
PDE3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | EC50 |
10 nM
Compound: DNMDP
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37984298] |
| HeLa | EC50 |
10 nM
Compound: DNMDP
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37984298] |
| HeLa | EC50 |
6.9 nM
Compound: DNMDP
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by Caspase-Glo reagent based assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by Caspase-Glo reagent based assay
|
[PMID: 31749907] |
| MCF7 | EC50 |
10 nM
Compound: DNMDP
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37984298] |
| NCI-H1563 | EC50 |
10 nM
Compound: DNMDP
|
Cytotoxicity against human NCI-H1563 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H1563 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37984298] |
| NCI-H2122 | EC50 |
10 nM
Compound: DNMDP
|
Cytotoxicity against human NCI-H2122 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H2122 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37984298] |
| PC-3 | EC50 |
10 nM
Compound: DNMDP
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37984298] |
| SK-MEL3 | EC50 |
12 nM
Compound: DNMDP
|
Cytotoxicity against human SK-MEL3 cells assessed as cell growth inhibition upto 10 uM measured after 48 hrs by Caspase-Glo reagent based assay
Cytotoxicity against human SK-MEL3 cells assessed as cell growth inhibition upto 10 uM measured after 48 hrs by Caspase-Glo reagent based assay
|
[PMID: 31749907] |
DNMDP (0-1000 μM; 48 hours) shows clear cell-selective cytotoxicity[1].
HeLa cells undergo apoptosis upon DNMDP treatment, indicates by caspase activity detected by a caspase-sensitive luciferase assay and by poly ADP ribose polymerase (PARP) cleavage. At a concentration of 100 nM, DNMDP specifically inhibits both PDE3A and PDE3B, weakly inhibits PDE10, and had little or no detectable effect on other phosphodiesterases[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NCI-H1563, NCI-H2122, HeLa, A549, MCF7, and PC3 cells
-
Concentration:0-1000 μM
-
Incubation Time:48 hours
-
Result:Showed an EC50 between 10 and 100 nM for two additional lung adenocarcinoma cell lines, NCI-H1563 and NCI-H2122, and for HeLa cervical carcinoma cells, but an EC50 greater than 1 µM for A549, MCF7, and PC3 cells.
Chemical Information
-
CAS No. 328104-79-6
-
Appearance Solid
-
Molecular Weight 304.34
-
Formula C15H20N4O3
-
Color Orange to red
-
SMILES
[O-][N+](C1=CC(C(C(C)C2)=NNC2=O)=CC=C1N(CC)CC)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : 50 mg/mL (164.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2858 mL | 16.4290 mL | 32.8580 mL | 82.1450 mL |
| 5 mM | 0.6572 mL | 3.2858 mL | 6.5716 mL | 16.4290 mL | |
| 10 mM | 0.3286 mL | 1.6429 mL | 3.2858 mL | 8.2145 mL | |
| 15 mM | 0.2191 mL | 1.0953 mL | 2.1905 mL | 5.4763 mL | |
| 20 mM | 0.1643 mL | 0.8214 mL | 1.6429 mL | 4.1072 mL | |
| 25 mM | 0.1314 mL | 0.6572 mL | 1.3143 mL | 3.2858 mL | |
| 30 mM | 0.1095 mL | 0.5476 mL | 1.0953 mL | 2.7382 mL | |
| 40 mM | 0.0821 mL | 0.4107 mL | 0.8214 mL | 2.0536 mL | |
| 50 mM | 0.0657 mL | 0.3286 mL | 0.6572 mL | 1.6429 mL | |
| 60 mM | 0.0548 mL | 0.2738 mL | 0.5476 mL | 1.3691 mL | |
| 80 mM | 0.0411 mL | 0.2054 mL | 0.4107 mL | 1.0268 mL | |
| 100 mM | 0.0329 mL | 0.1643 mL | 0.3286 mL | 0.8214 mL |
Powered by Bioz